Introduction: The study aimed to present our experience of surgical treatment for urorectal fistulas (URF) that develop after cancer surgery. Materials and Methods: Fourteen patients with URF who were treated at our institution from 2005 through 2015 were retrospectively analyzed. Among these, 7 patients had previous surgical treatment of prostate cancer (PC) and the other 7 had been treated for rectal cancer (RC). The fistula was resected through a perineal incision, and the urinary and fecal defects were separately closed with the hinge flap method followed by interposition of a muscle flap transfer. Results: The overall fistula closure rate was 79%. Although the closure rate of the URF was lower in patients with previous RC surgery compared to the PC patients (57 vs. 100%), it did not reach statistical significance. Conclusions: URF treatment using an interposition muscle flap offers a high success rate of fistula closure. However, complicated fistulas occurring after RC surgery involving the prostate or the seminal vesicle might be difficult to repair by this surgery alone.

Keywords:
Urorectal fistula, Interposition muscle flap, Prostate cancer, Rectal cancer
1.
Hechenbleikner EM, Buckley JC, Wick EC: Acquired rectourethral fistulas in adults: a systematic review of surgical repair techniques and outcomes. Dis Colon Rectum 2013;56:374-383.
2.
Nakajima K, Sugito M, Nishizawa Y, et al: Rectoseminal vesicle fistula as a rare complication after low anterior resection: a report of three cases. Surg Today 2013;43:574-579.
3.
Thomas C, Jones J, Jager W, et al: Incidence, clinical symptoms and management of rectourethral fistulas after radical prostatectomy. J Urol 2010;183:608-612.
4.
Masuda T, Kinoshita H, Nishida S, et al: Rectal injury during laparoscopic radical prostatectomy: detection and management. Int J Urol 2010;17:492-495.
5.
Vanni AJ, Buckley JC, Zinman LN: Management of surgical and radiation induced rectourethral fistulas with an interposition muscle flap and selective buccal mucosal onlay graft. J Urol 2010;184:2400-2404.
6.
Ryan JA Jr, Beebe HG, Gibbons RP: Gracilis muscle flap for closure of rectourethral fistula. J Urol 1979;122:124-125.
7.
Nyam DC, Pemberton JH: Management of iatrogenic rectourethral fistula. Dis Colon Rectum 1999;42:994-997; discussion 997-999.
8.
Mundy AR, Andrich DE: Urorectal fistulae following the treatment of prostate cancer. BJU Int 2011;107:1298-1303.
9.
Kanehira E, Tanida T, Kamei A, et al: Transanal endoscopic microsurgery for surgical repair of rectovesical fistula following radical prostatectomy. Surg Endosc 2015;29:851-855.
10.
Hanna JM, Turley R, Castleberry A, et al: Surgical management of complex rectourethral fistulas in irradiated and nonirradiated patients. Dis Colon Rectum 2014;57:1105-1112.
11.
Noldus J, Fernandez S, Huland H: Rectourinary fistula repair using the Latzko technique. J Urol 1999;161:1518-1520.
12.
Kasraeian A, Rozet F, Cathelineau X, et al: Modified York-Mason technique for repair of iatrogenic rectourinary fistula: the montsouris experience. J Urol 2009;181:1178-1183.
13.
Pfalzgraf D, Isbarn H, Reiss P, et al: Outcomes after recto-anastomosis fistula repair in patients who underwent radical prostatectomy for prostate cancer. BJU Int 2014;113:568-573.
14.
Saito N, Ito M, Kobayashi A, et al: Long-term outcomes after intersphincteric resection for low-lying rectal cancer. Ann Surg Oncol 2014;21:3608-3615.
© 2017 S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.